In summary, MannKind Corporation’s earnings call reflects a positive outlook, driven by strong financial performance and strategic advancements in its product pipeline. Despite challenges in certain ...

MannKind Corporation ( MNKD) has disclosed a new risk, in the Capital Markets category. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...

Westlake Village-based MannKind Corporation is receiving some extra help to advance some of its short and long-term growth strategies. Announced Aug. 6, MannKind, a biotech company focused on inhaled ...

Q2 2025 Earnings Call Transcript August 6, 2025 Operator: Good morning, and welcome to the MannKind Corporation Second ...

MannKind saw decent growth from its two core products in Q2 and just signed a new non-dilutive financing agreement with ...

The biopharmaceutical company posted adjusted earnings of $0.05 per share for the second quarter, matching analyst estimates. However, revenue came in at $76.53 million, below the consensus estimate ...

The company submitted its lead inhaled insulin product for expanded FDA approval and secured $500 million in funding, it said ...

Conference call today at 9:00 am ET2Q 2025 revenues of $76.5M, +6% v. 2Q 2024YTD 2025 revenues of $154.9M, +12% v. YTD ...

Analysts anticipate MannKind to report an earnings per share (EPS) of $0.06. The announcement from MannKind is eagerly ...

MannKind Corp (NASDAQ:MNKD) is set to release its Q2 2025 earnings on Aug 6, 2025. The consensus estimate for Q2 2025 revenue ...

MannKind Corporation (NASDAQ: MNKD) is one of the best strong buy penny stocks to buy now. In a report released on July 29, ...

MannKind Corporation (NASDAQ:MNKD) is one of the penny stocks that will skyrocket. On July 16, H.C. Wainwright assumed ...